US Stock MarketDetailed Quotes
KYTX Kyverna Therapeutics
- 9.710
- -0.300-3.00%
Close Jul 22 16:00 ET
- 9.510
- -0.200-2.06%
Post 19:03 ET
418.65MMarket Cap-5513P/E (TTM)
10.350High9.550Low249.47KVolume10.350Open10.010Pre Close2.44MTurnover1.50%Turnover RatioLossP/E (Static)43.12MShares35.06052wk High1.16P/B161.91MFloat Cap6.75052wk Low--Dividend TTM16.68MShs Float35.060Historical High--Div YieldTTM7.99%Amplitude6.750Historical Low9.791Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Kyverna Therapeutics Stock Forum
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet